A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
A phase 1/2 trial of GFH375, Cetuximab, Paclitaxel / nab-paclitaxel in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.
Overview
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07259590 by Genfleet Therapeutics (Shanghai) Inc., with 126 participants planned, started 2025-10-21 and due to reach its primary completion in 2027-07. Interventions recorded: GFH375, GFH375. Conditions listed: Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Gemcitabine, Paclitaxel / nab-paclitaxel, Colorectal cancer.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Cetuximab, Gemcitabine, Paclitaxel / nab-paclitaxel, Colorectal cancer.
- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Shares Cetuximab, Colorectal cancer.
- PersonDongsheng Tu
Shares Cetuximab, Colorectal cancer.
- TrialStudy of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Shares Gemcitabine, Paclitaxel / nab-paclitaxel.
- PersonCarsten Bokemeyer
Shares Cetuximab, Colorectal cancer.
- TrialA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic
Shares Cetuximab, Colorectal cancer.
- TrialA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Shares Cetuximab, Gemcitabine, Colorectal cancer.